Acne

Stiefel Laboratories, Inc. Enters into Strategic Collaboration with Allergan, Inc. to Expand and Strengthen Dermatologic Product Offering

Acne Library Library Home This article was published in Biotech Business Week, which you can subscribe to online.

Under the terms of the transaction, Stiefel will utilize Allergan's proprietary technology and tazarotene in several different ways. Stiefel's U.S. sales force will co-promote Allergan's TAZORAC(R) (tazarotene) to dermatologists. Stiefel also will capitalize on its existing patent-protected technology and Allergan's innovative tazarotene compound to bring unique therapeutic options to market for a common dermatological disease.

"This is a great opportunity," said Bill Humphries, Chief Commercial Officer, Stiefel Laboratories. "TAZORAC(R) will provide the perfect complement to our acne portfolio, which also includes Duac(R), and it will allow Stiefel to offer best-in-class topical acne treatments to our customers. Given our long-standing and well-established presence in the dermatology arena, we will be able make an immediate and important impact with TAZORAC(R)."

"Allergan is pleased to enter into a relationship with Stiefel to further strengthen our presence in the medical dermatology market," said Julian Gangolli, Allergan's Corporate Vice President and President of North America Pharmaceuticals. "The TAZORAC(R) brand is already widely recognized by dermatologists as an effective treatment option for acne and psoriasis. Stiefel's experience, expertise and capabilities in the dermatology market will be instrumental in helping to develop and market new products involving tazarotene for global dermatological use."

According to Gavin Corcoran, Senior Vice President, Global Research and Development, Stiefel Laboratories, the development agreements with Allergan are an integral component of Stiefel's overall growth strategy.

"This strategic partnership between Stiefel and Allergan epitomizes the type of development agreements Stiefel is seeking to enhance our robust pipeline," Corcoran said. "We are able to integrate Stiefel's cutting-edge technology and products with Allergan's proprietary tazarotene compound in order to provide physicians and patients with advanced solutions for the prevention and treatment of common skin conditions."

Keywords: Acne Vulgaris, Business, Drugs, Patent Actions, Patents Actions, Pharmaceuticals, Tazarotene, Tazorac, Therapy, Treatment, Stiefel Laboratories Inc.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.